Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

Benzinga Newsdesk www.benzinga.com Neutral 74.2%

Neg 0% Neu 74.2% Pos 0%

Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.